myChoice HRD: The optimal approach to the select patient with OC who can benefit from a PARPi treatment.

Mutations in BRCA1 and BRCA2 genes are the main cause of genomic instability, but beyond that, several other causes like other genes involved in the homologous recombination pathway or BRCA1 promoter methylation can result in HR deficiency. However, many causes have yet to be identified.

myChoice HRD is the most comprehensive tumor test to determine HRD status by measuring BRCA1 and BRCA2 mutation, and Genomic Instability Status through proprietary methods. It allows the identification of more ovarian cancer tumors with HRD than other testing methods. In this webinar, we will discuss how myChoice HRD was developed and how this assay differs from others.

Click here to watch the webinar on-demand